Keith James, President Ferring Research Institute, Inc., and Senior Vice President R&D

Dr. Keith James joined Ferring on January 2012 as the Vice President of Therapeutic Innovation. He was promoted to President Ferring Research Institute, Inc., and Senior Vice President R&D in December 2012. Before joining Ferring, Dr. James spent 29 years working at Pfizer. Throughout his tenure at Pfizer, Dr. James’ appointments included positions as Vice President for Discovery Research at the Pfizer Sandwich site; Senior Vice President of the Pfizer Strategic Management Group in New London, CT; Vice President of Discovery Research, at the Pfizer site in Ann Arbor, MI; and Research Site Head at the Pfizer La Jolla site.

Dr. James is a graduate of Imperial College, London and received his Ph.D. in Chemistry from Cambridge University.  He spent two years as a NATO Research Fellow at Stanford University, CA and Columbia University, NY before beginning his drug discovery career.

Claudio Schteingart, Vice President, Science & Technology-Research

Dr. Claudio Schteingart joined Ferring on July 1996.  He is the Vice President, Science & Technology-Research and his responsibilities include evaluation of new technologies for the discovery and development of novel peptide therapeutics. In addition, he also provides guidance to drug discovery programs and support to drug candidates in development.

Dr. Schteingart’s Ferring career started with a position as a research chemist where he participated in the discovery of the peptidic GnRH antagonist degarelix, launched in 2009, and five other peptidic drug candidates in various stages of clinical development for women’s health, critical care medicine, and gastroenterology.

Dr. Schteingart received a Ph.D. in Chemistry at the University of Buenos Aires, Argentina. After postdoctoral studies in the Department of Chemistry at the University of California, San Diego, he moved to the Department of Medicine where he carried out research in the chemistry, physiology, metabolism, and physicochemical properties of biliary components and lipids.

Gebhard Neyer, Senior Director of Program Management

Dr. Gebhard Neyer joined Ferring on February 2008 and is the Senior Director of Program Management.

After completing a post-doctoral fellowship in organic chemistry under Prof. Olah at the University of Southern California, Dr. Neyer worked for LXN Corporation, a start-up company working in the diabetes field. In addition, he served as project leader at Neurocrine Biosciences, as well as team leader at Pfizer, La Jolla, where he managed various small molecule and biologics projects in neurology, oncology and ophthalmology.

Dr. Neyer has over 15 years of experience in all phases of drug and diagnostics R&D, project and portfolio management, team leadership and research management.

He is a native of Austria and holds a Ph.D. in chemistry from the Technische Universität München, Germany, and an MBA from California State University, Long Beach.

Paul Acosta, Associate Director of Human Resources and Administration

Paul Acosta joined Ferring in May 2012 as the Associate Director of Human Resources and Administration, and is responsible for upholding The Ferring Philosophy that People Come First.

Prior to joining Ferring, Mr. Acosta held several progressively more senior Human Resources leadership positions at Genoptix, a Novartis Company, Avanir Pharmaceuticals and Chugai Pharma USA. He has 20 years of experience in all facets of Human Resources including: recruitment, performance management, compensation, employee relations, training and development, succession planning and organization design.  Paul holds a Bachelor’s degree in Business Administration from National University, San Diego, California.